Development and standardization of multiplexed antibody microarrays for use in quantitative proteomics

Table 8 Array 4: Averaged LLQs/ULQs in pg/mL obtained from 15 point standard titrations

Feature	B	W	A	W+A	LLQ (pg/mL)	ULQ (pg/mL)
ALCAM	0	100	0	100	991	145528
CD27	10	90	0	90	508	148468
CD30	53	47	0	47	2460	128280
CTACK	0	100	0	100	43	10691
Eot-3	37	63	0	63	130	28149
FGF-2	31	67	2	69	102	5814
FGF-4	57	43	0	43	260	14563
Follistatin	8	92	0	92	138	57120
GRO-g	12	75	13	88	59	4344
I-TAC	11	89	0	89	16	6191
ICAM-1	1	76	23	99	289	29018
IFN-g	39	60	1	61	14	7365
IFN-w	37	58	5	63	1177	42508
IGF-II	0	85	15	100	46	13538
IGF-1R	33	67	0	67	330	91601
IGFBP-1	2	72	26	98	272	85578
IGFBP-3	0	7	93	100	5530	30760
IGFBP-4	0	80	20	100	410	22880
IL-1 sR1	30	70	0	70	534	54857
IL-10rb	12	88	0	88	28	11331
IL-16	28	72	0	72	724	86874
IL-1 srII	19	81	0	81	509	76440
IL-2rb	71	29	0	29	10277	107828
LT bR	14	86	0	86	34	37957
Lymphotactin	28	72	0	72	166	9216
M-CSF R	0	91	9	100	1951	121318
MIP-3a	16	84	0	84	13	3389
MMP-10	10	90	0	90	158	42033
PDGF-Ra	30	66	5	70	8112	151722
PF4	0	23	77	100	67	5458
TGF-a	33	67	0	67	35	2678
TIMP-2	0	12	88	100	130	25224
TRAIL R1	33	67	0	67	21	10956
VAP-1	1	23	76	99	4624	150226
VE-cadherin	1	94	5	99	2652	146826
VEGF-D	34	66	0	66	1370	100539
b-NGF	27	73	0	73	141	12400

Data shown is from titrations run in 8 client projects (1000 clinical samples surveyed) covering 8 diverse disease areas. The percentage of samples falling below (B), within (W) or above (A) the linear range of detection are presented. The analyte was considered to be detectable if the W+A percentage was above 50%.